In this study, thus, we searched for a model superior to those reported previously by determining the feasibility of a radiomics-based eXtreme Gradient Boosting (XGBoost) model to identify MGMT promoter methylation status in patients with IDH1 wildtype GBM. Here, MGMT is linked to glioblastoma.